IPO registrations (S-1, F-1) · Registrants
Prelude Therapeutics Inc
- SEC CIK
- 1678660 · filings on EDGAR ↗
- Former names
- Prelude Therapeutics Inc. (2016–2017)
- Registration
- Form S-1, first filed 2020-09-04, last 2021-01-04; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2020-09-25; declared effective 2020-09-24
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 175 INNOVATION BOULEVARD, Wilmington, DE 19805
- EIN
- 81-1384762
- Ticker
- PRLD (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Prelude Therapeutics Inc on the corporate pages
Offering terms
- Proposed price range
- $17.00–$19.00 per share (S-1/A filed 2020-09-21)
- Final price
- $19.00 per share, within the range (424B4 filed 2020-09-25, an initial public offering)
- Shares sold
- 8,325,000
- Gross proceeds
- $158,175,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol PRLD
- Lead underwriters
- Morgan Stanley; Goldman Sachs (2,913,750 shares); BofA Securities (2,289,375 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: PRELUDE THERAPEUTICS INCORPORATED Fuzzy (name and state)
- Form 5500 plan sponsor: PRELUDE THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: Prelude Therapeutics Inc EXACT (CIK (EXACT))
- SEC filer: Prelude Therapeutics Inc EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-09-04 | S-1 | S-1 (registration) | Prelude Therapeutics Inc | 0001193125-20-240138 ↗ |
| 2020-09-16 | S-1/A | S-1/A (amendment) | Prelude Therapeutics Inc | 0001193125-20-246920 ↗ |
| 2020-09-21 | S-1/A | S-1/A (amendment) | Prelude Therapeutics Inc | 0001193125-20-249549 ↗ |
| 2020-09-24 | EFFECT | EFFECT (declared effective) | Prelude Therapeutics Inc | 9999999995-20-002573 ↗ |
| 2020-09-25 | 424B4 | 424B4 (final prospectus) | Prelude Therapeutics Inc | 0001193125-20-254577 ↗ |
| 2021-01-04 | S-1 | S-1 (registration) | Prelude Therapeutics Inc | 0001193125-21-000946 ↗ |
| 2021-01-06 | S-1MEF | S-1MEF (added securities) | Prelude Therapeutics Inc | 0001193125-21-003474 ↗ |
| 2021-01-06 | EFFECT | EFFECT (declared effective) | Prelude Therapeutics Inc | 9999999995-21-000059 ↗ |
| 2021-01-07 | 424B4 | 424B4 (final prospectus) | Prelude Therapeutics Inc | 0001193125-21-004168 ↗ |
| 2021-11-24 | EFFECT | EFFECT (declared effective) | Prelude Therapeutics Inc | 9999999995-21-004484 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-21 | S-1/A | registration statement | $17.00–$19.00 | 8,325,000 | - | Nasdaq PRLD | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2020-09-25 | 424B4 | final prospectus | $19.00 | 8,325,000 | $158,175,000 | Nasdaq PRLD | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| 667, L.P. | Director,TenPercentOwner | 13 | 2020–2026 | ||
| Baker Bros. Advisors (GP) LLC | Director,TenPercentOwner | 13 | 2020–2026 | ||
| BAKER BROS. ADVISORS LP | Director,TenPercentOwner | 13 | 2020–2026 | ||
| Baker Brothers Life Sciences LP | Director,TenPercentOwner | 13 | 2020–2026 | ||
| BAKER FELIX | Director,TenPercentOwner | 13 | 2020–2026 | ||
| BAKER JULIAN | Director,TenPercentOwner | 13 | 2020–2026 | ||
| Bonita David P | Director,TenPercentOwner | 11 | 2020–2026 | ||
| Combs Andrew | Officer | Chief Chemistry Officer; EVP, Head of Chemistry | 12 | 2020–2026 | |
| Dier Mardi | Director | 8 | 2020–2025 | ||
| FRIEDMAN PAUL A | Director | 8 | 2020–2026 | ||
| Mauro David J | Officer | Chief Medical Officer | 12 | 2020–2021 | |
| Morosini Deborah | Officer | EVP, Chief of Clinical Affairs | 9 | 2020–2022 | |
| Neu Kelvin | Director | 1 | 2020 | ||
| ORBIMED ADVISORS LLC | Director,TenPercentOwner | 6 | 2020–2026 | ||
| OrbiMed Capital GP VI LLC | Director,TenPercentOwner; TenPercentOwner | 6 | 2020–2026 | ||
| Pierce Christopher | Officer | EVP and Chief of Business Oper | 7 | 2020–2021 | |
| Piper Brian | Officer | Chief Financial Officer | 4 | 2020–2021 | |
| Sandor Victor | Director | 11 | 2020–2026 | ||
| Scherle Peggy | Officer | Chief Scientific Officer | 13 | 2020–2026 | |
| Vaddi Krishna | Director,Officer | CEO; President, CEO | 19 | 2020–2026 | |
| ORBIMED CAPITAL LLC | Director,TenPercentOwner | 4 | 2020–2026 | ||
| Babler Martin | Director | 7 | 2021–2026 | ||
| Chardonnet Laurent | Officer | Chief Financial Officer | 11 | 2021–2024 | |
| Huang Jane | Officer | President, CMO | 16 | 2022–2025 | |
| Lim Bryant David | Officer | Chief Legal Counsel, Corp Sec.; Chief Legal Officer, Corp Sec.; CLO, CFO, Corp Sec.; CLO, Interim CFO, Corp Sec. | 8 | 2023–2026 | |
| Scherer Paul C | Director | 1 | 2025 | ||
| Dorton Katina | Director | 3 | 2025–2026 | ||
| Brusky Sean P. | Officer | Chief Business Officer | 1 | 2026 | |
| Morris Charles Q | Officer | Chief Medical Officer | 2 | 2026 | |
| OrbiMed Genesis GP LLC | Director,TenPercentOwner | 1 | 2026 | ||
| Kolchinsky Peter | TenPercentOwner | 2 | 2026 | ||
| RA Capital Healthcare Fund LP | TenPercentOwner | 2 | 2026 | ||
| RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | 2 | 2026 | ||
| Shah Rajeev M. | TenPercentOwner | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-08-28 | Prelude Therapeutics Inc | Biotechnology | $49,999,969 | $49,999,969 | 7 | 1 |
| 2019-06-17 | Prelude Therapeutics Inc | Biotechnology | $59,999,998 | $29,999,999 | 6 | 1 |
| 2017-10-20 | Prelude Therapeutics Inc | Biotechnology | $29,999,998 | $29,999,998 | 7 | 2 |
| 2016-07-11 | Prelude Therapeutics Inc. | Biotechnology | $5,000,000 | $5,000,000 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | PRELUDE THERAPEUTICS INCORPORATED | DE | State business registries | name and state |
| Plan sponsor | PRELUDE THERAPEUTICS, INC | DE | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Prelude Therapeutics Inc | DE | Form D private offerings | CIK (EXACT) |
| SEC filer | Prelude Therapeutics Inc | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Prelude Therapeutics Incorporated | DE | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | PRELUDE THERAPEUTICS INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, DE first:
- Merus N.V. DE
- NRX Pharmaceuticals, Inc. DE
- Applied Molecular Transport Inc. DE
- Lomond Therapeutics Holdings, Inc. DE
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- Catalent, Inc. NJ
- Korro Bio, Inc. MA
In other datasets, the same topic (Health) in DE:
- Nonprofit: 1212 CORPORATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health